Key Laboratory for Protein and Peptide Pharmaceuticals, National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
University of Chinese Academy of Sciences, Beijing, 100039, China.
Appl Microbiol Biotechnol. 2019 Sep;103(18):7703-7717. doi: 10.1007/s00253-019-10030-x. Epub 2019 Jul 29.
G protein-coupled receptors (GPCRs), also known as seven-transmembrane domain receptors, are among the most important targets against which many small molecule drugs have been developed. However, only two antibody drugs targeting GPCRs have been approved for clinical use although many antibody drugs against non-GPCR protein targets have been successfully developed for various disease indications. One of the challenges for developing anti-GPCR drugs is the high difficulty to perform affinity maturation due to their insolubility in aqueous solutions. To address this issue, CHO cell display libraries of single-chain variable fragments (scFvs) and full-length antibodies were maturated directly against vesicle probes prepared from CHO cells displaying the endothelin A receptor (ETaR) GPCR. The probe in the vesicle form ensures the physiological conformation and functional activity of the protein and avoids issues with membrane protein insolubility. The size of the vesicle had a clear effect on protein-ligand interaction; we used small-sized vesicles with low expression levels of GPCRs for the affinity maturation. Four rounds of affinity maturation combining vesicles as probes with the CHO cell display platform improved affinity by 13.58-fold for scFvs and 5.05-fold for full-length antibodies. We expect that this method will not only be used for the affinity maturation of antibodies against GPCRs but will also be used to mature antibodies for other types of proteins where the conformation/activity of which depends on the proper membrane environment.
G 蛋白偶联受体(GPCRs),也称为七跨膜域受体,是许多小分子药物的重要靶点之一。然而,尽管已经成功开发了许多针对非 GPCR 蛋白靶点的抗体药物用于各种疾病适应症,但只有两种针对 GPCR 的抗体药物获得批准用于临床使用。开发抗 GPCR 药物的挑战之一是由于它们在水溶液中的不溶性,使得亲和力成熟的难度很高。为了解决这个问题,我们直接针对CHO 细胞展示的内皮素 A 受体(ETaR)GPCR 的囊泡探针,对单链可变片段(scFvs)和全长抗体的 CHO 细胞展示文库进行了亲和力成熟。囊泡形式的探针确保了蛋白质的生理构象和功能活性,并避免了膜蛋白不溶性的问题。囊泡的大小对蛋白质-配体相互作用有明显的影响;我们使用小尺寸、低表达水平的 GPCR 囊泡进行亲和力成熟。四轮亲和力成熟将囊泡作为探针与 CHO 细胞展示平台相结合,使 scFvs 的亲和力提高了 13.58 倍,全长抗体的亲和力提高了 5.05 倍。我们预计这种方法不仅将用于 GPCR 抗体的亲和力成熟,也将用于成熟其他类型的蛋白质的抗体,这些蛋白质的构象/活性取决于适当的膜环境。